Clinical Trial Update: Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

View source ↗

Summary

The ClinicalTrials.gov update reports results comparing the incidence of respiratory tract adverse events in patients with pulmonary arterial hypertension treat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Tyvaso (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Status: COMPLETED | Results posted: 2016-02-17